tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

Revive Therapeutics Prioritizes Bucillamine Development
Company AnnouncementsRevive Therapeutics Prioritizes Bucillamine Development
2d ago
Revive Therapeutics announces strategic focus on Bucillamine
PremiumThe Fly
Revive Therapeutics announces strategic focus on Bucillamine
2d ago
Revive Therapeutics Explores Bucillamine for Nerve Agents and Viral Threats
PremiumCompany Announcements
Revive Therapeutics Explores Bucillamine for Nerve Agents and Viral Threats
23d ago
Revive Therapeutics provides information update on Bucillamine and Mpox
PremiumThe Fly
Revive Therapeutics provides information update on Bucillamine and Mpox
23d ago
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections
PremiumPress Releases
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections
23d ago
Revive Therapeutics Tests Treatment for Nerve Agents
PremiumCompany AnnouncementsRevive Therapeutics Tests Treatment for Nerve Agents
3M ago
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
Premium
Press Releases
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
3M ago
Revive Therapeutics Advances Long COVID Treatment
Premium
Company Announcements
Revive Therapeutics Advances Long COVID Treatment
3M ago
Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
PremiumPress Releases
Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
3M ago
Revive provides update on FDA Type C meeting for study of Bucillamine
PremiumThe Fly
Revive provides update on FDA Type C meeting for study of Bucillamine
3M ago
Revive Therapeutics Advances Long COVID Detection Kit
PremiumCompany Announcements
Revive Therapeutics Advances Long COVID Detection Kit
3M ago
Revive provides update from FDA meeting for Long COVID diagnostic product
PremiumThe Fly
Revive provides update from FDA meeting for Long COVID diagnostic product
3M ago
Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
PremiumPress ReleasesRevive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
3M ago
Revive Therapeutics Advances Long COVID Treatment
Premium
Company Announcements
Revive Therapeutics Advances Long COVID Treatment
5M ago
Revive Therapeutics granted Type C meeting request by FDA for bucillamine
Premium
The Fly
Revive Therapeutics granted Type C meeting request by FDA for bucillamine
5M ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
PremiumPress Releases
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
5M ago
Revive Therapeutics Advances Long COVID Diagnostic
PremiumCompany Announcements
Revive Therapeutics Advances Long COVID Diagnostic
5M ago
Revive Therapeutics announces FDA acceptance of meeting request
PremiumThe Fly
Revive Therapeutics announces FDA acceptance of meeting request
5M ago
Revive Therapeutics Advances Psilocybin Study
PremiumCompany Announcements
Revive Therapeutics Advances Psilocybin Study
6M ago
Revive provides update on psilocybin study for methamphetamine use disorder
PremiumThe FlyRevive provides update on psilocybin study for methamphetamine use disorder
6M ago
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
Premium
Press Releases
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
6M ago
Revive Therapeutics Eyes FDA Approval for COVID Treatment
Premium
Company Announcements
Revive Therapeutics Eyes FDA Approval for COVID Treatment
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >